Post-treatment human papillomavirus antibody kinetics in cervical cancer patients

Piontek, Till; Harmel, Christoph; Pawlita, Michael; Carow, Katrin; Schröter, Juliane; Runnebaum, Ingo B.; Graw, Frederik; Waterboer, Tim

doi:10.1098/rstb.2018.0295

Cited by 6 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Piontek and co-workers conducted a study in 184 HPV16-driven invasive cervical cancer patients to characterize post-treatment AB-dynamics using multiplex HPV serological testing (GST-derived antigens) (23). They showed that L1 antibody levels are stable over time whereas E6 and E7 AB levels decreased after cervical cancer treatment (23). Both studies con rm the hypothesis that L1 IgG-ABs remain stable over time.…”

Section: Discussionmentioning

confidence: 91%

“…In the past few years different serological tests have been studied in HPV-positive OPSCC. Antibody-based serological tests revealed that E6 and E7 oncoproteins of high-risk HPVs strongly correlate to HPV-driven malignancies, whereas L1-antibodies are regarded as cumulative-exposure markers (22,23). Oton-Gonzales et al used a commercial kit (HPV16 L1, Cusabio, Houston, TX, USA) to investigate serological L1-IgG kinetics in 20 HPV-positive HNSCC cases (22).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

Weiland,

Zgubic,

Brcic

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Although the therapy response of HPV-positive oropharyngeal carcinomas (OPSCC) is known to be significantly better compared to HPV-negative tumors, about 25% of them will have a recurrence within the first 5 years after therapy. Therefore, it is of great scientific interest to find relevant biomarkers to identify subgroups with a poorer prognosis. In this prospective observational study, we examine for the first time the behavior of HPV-L1 antibody subclasses IgA, IgG, and IgM in HPV-positive OPSCC patients under therapy. Material and Methods The study cohort included patients with HPV-positive OPSCCs from the Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Graz. Serum samples were collected before and during tumor-specific therapy and follow-up. They were analyzed for the presence of HPV-L1 antibody (AB) subclasses IgA, IgM, and IgG using an HPV-L1-specific immuno-assay. In addition, a PCR-based HPV-DNA detection and subtyping from the tumor tissue was performed. Statistical analysis included Chi2- and Kruskal-Wallis-H-Test for significance testing. Correlation between two ordinal sizes has been tested using Spearmen-Rho. Results Altogether, 34 patients with a mean age of 63.5 years and a mean follow-up of 55 months were included. The most common L1-AB-subclass pattern was characterized by IgG > > IgA > IgM (13 cases) without significant fluctuation. The second most common pattern was IgG > IgA > IgM (6 cases). In 5 cases an antibody pattern of IgA > IgG > IgM while in 4 cases IgG = IgA > IgM was seen. Three out of 4 recurrences had previously shown an increase in IgG antibodies. Patients with excessive IgG levels tended to have higher tumor stages. IgA dominance at diagnosis was associated with better disease-free survival. Conclusions In this prospective longitudinal observational study, we show for the first time the behavior of HPV-L1 antibody subclasses IgA, IgG, and IGM in HPV-positive OPSCC patients under therapy. IgA dominance at diagnosis was associated with better disease-free survival, whereas a higher IgG/IgA ratio correlated with higher tumor stages. In three recurrent tumors, an increase in the IgG AB level could be shown beforehand. HPV-L1 AB-subclass detection might be of use for future risk stratification in HPV-pos. OPSCC patients.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

Weiland,

Zgubic,

Brcic

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Additionally, it has been reported that E6 and E7 positivity correlates with better survival but worse tumor grade and stage [14]. However, no study to our knowledge has yet identified oncoprotein titer variation throughout the disease course to be useful for predicting HPV HNC clinical outcome [19][20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx

Johnson

Hall

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( n = 48 ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( p = .004 ) with 100% specificity as a predictive test.

show abstract

“…Nevertheless, E6 and E7 antibody levels undergo decay after cervical cancer treatment ( 68 ). Recurrence of squamous high-grade intraepithelial neoplasia (VIN3), which happens in approximately 30% of women after treatment, was less frequent among those with natural HPV16 antibodies in the sera ( 69 ).…”

Section: Immunological Methods Based On Hpv Proteins For Diagnosismentioning

confidence: 99%

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Dong

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Infection with human papillomavirus (HPV) is one of the main causes of malignant neoplasms, especially cervical, anogenital, and oropharyngeal cancers. Although we have developed preventive vaccines that can protect from HPV infection, there are still many new cases of HPV-related cancers worldwide. Early diagnosis and therapy are therefore important for the treatment of these diseases. As HPVs are the major contributors to these cancers, it is reasonable to develop reagents, kits, or devices to detect and eliminate HPVs for early diagnosis and therapeutics. Immunological methods are precise strategies that are promising for the accurate detection and blockade of HPVs. During the last decades, the mechanism of how HPVs induce neoplasms has been extensively elucidated, and several oncogenic HPV early proteins, including E5, E6, and E7, have been shown to be positively related to the oncogenesis and malignancy of HPV-induced cancers. These oncoproteins are promising biomarkers for diagnosis and as targets for the therapeutics of HPV-related cancers. Importantly, many specific monoclonal antibodies (mAbs), or newly designed antibody mimics, as well as new immunological kits, devices, and reagents have been developed for both the immunodiagnosis and immunotherapeutics of HPV-induced cancers. In the current review, we summarize the research progress in the immunodiagnosis and immunotherapeutics based on HPV for HPV-induced cancers. In particular, we depict the most promising serological methods for the detection of HPV infection and several therapeutical immunotherapeutics based on HPV, using immunological tools, including native mAbs, radio-labelled mAbs, affitoxins (affibody-linked toxins), intracellular single-chain antibodies (scFvs), nanobodies, therapeutical vaccines, and T-cell-based therapies. Our review aims to provide new clues for researchers to develop novel strategies and methods for the diagnosis and treatment of HPV-induced tumors.

show abstract

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients

Abstract: One contribution of 16 to a theme issue 'Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses'. Subject Areas:health and disease and epidemiology, immunology

Cited by 6 publications

References 48 publications

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

Trending Anti-E7 Serology Predicts Mortality and Recurrence of HPV-Associated Cancers of the Oropharynx

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Contact Info

Product

Resources

About